Table 1.
General characteristic of the study population stratified by drug and gender
| Parameters | HIV Patients | Male Patients | Female Patients | |||
| HAART naïve | On HAART | HAART naïve | On HAART | HAART naïve | On HAART | |
| Age (yrs) | 33.42 ± 0.88 | 36.91 ± 0.77** | 36.68 ± 2.15 | 39.63 ± 1.68 | 32.17 ± 0.89‡ | 36.10 ± 0.85§§ |
| WT (kg) | 48.93 ± 1.24 | 54.92 ± 3.61* | 54.08 ± 2.44 | 75.50 ± 2.50†† | 47.00 ± 1.34‡‡ | 51.18 ± 3.04## |
| CD4 (cell mm-3) | 272.60 ± 13.24 | 315.30 ± 13.92* | 251.60 ± 26.40 | 277.70 ± 29.85 | 295.50 ± 17.33 | 326.30±15.78 |
| CD3 (cell mm-3) | 1243.00 ± 43.55 | 1216.00 ± 45.19 | 1251.00 ± 89.33 | 1148.00 ± 92.36 | 1276.00 ± 56.32 | 1238.00 ± 52.08 |
| TWBC (x 103 µl−1) | 5.19 ± 0.18 | 4.39 ± 0.12** | 5.53 ± 0.41 | 4.32 ± 0.24† | 5.14 ± 0.23 | 4.41 ± 0.14§ |
| TLC (x 103 µl−1) | 2.81 ± 0.09 | 2.73 ± 0.08 | 2.86± 0.21 | 2.48 ± 0.18 | 2.79 ± 0.12 | 2.79 ± 0.09 |
| LC (%) | 55.48 ± 1.03 | 62.49 ± 1.00*** | 53.79 ± 2.18 | 57.72 ± 2.57 | 55.97 ± 1.38 | 63.77 ± 1.05§§§,# |
| RBC (x 106 µl−1) | 3.55 ± 0.04 | 3.31 ± 0.05*** | 3.67 ± 0.11 | 3.51 ± 0.09 | 3.51 ± 0.05 | 3.25 ± 0.05§§§,# |
| HB (g dl−1) | 9.80 ± 0.12 | 10.59 ± 0.15 | 10.59 ± 0.29 | 11.54 ± 0.33† | 9.45 ± 0.13‡‡‡ | 10.33 ± 0.16§§§,### |
| PCV (%) | 32.64 ± 0.48 | 35.68 ± 0.55*** | 35.19 ± 1.19 | 38.00 ± 0.10 | 31.33 ± 0.52‡‡‡ | 35.06 ± 0.63§§§,### |
| MCV (fL) | 93.02 ± 0.94 | 110.50 ± 1.33*** | 96.32 ± 2.30 | 112.5 ± 2.79††† | 90.99 ± 1.11‡ | 109.90± 1.51§§§ |
| MCH (pg) | 27.92 ± 0.27 | 32.60 ± 0.50*** | 29.61 ± 0.66 | 33.51 ± 0.81††† | 27.19 ± 0.31‡‡‡ | 32.35 ± 0.59§§§ |
| MCHC (g dl−1) | 30.30 ± 0.25 | 29.66 ± 0.40 | 31.10 ± 0.65 | 29.95 ± 0.49 | 30.17 ± 0.31 | 29.58 ± 0.48 |
| RDW (%) | 20.88 ± 0.50 | 18.64 ± 0.52 | 21.91 ± 1.39 | 17.26 ± 0.59† | 20.73 ± 0.59 | 18.98 ± 0.63§ |
| PLT (x 103 µl−1) | 174.40 ± 7.20 | 148.80 ± 6.07* | 178.5 ± 18.82 | 163.1 ± 14.09 | 178.10 ± 8.29 | 144.90 ± 6.69§§ |
| MPV (fL) | 11.25 ± 0.22 | 11.88 ± 0.20* | 11.30 ± 0.48 | 11.80 ± 0.32 | 10.99 ± 0.27 | 11.90 ± 0.25§ |
Results are presented as means ± SEM. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 indicates the level of significance when the HAART naïve were compared to those on HAART (unpaired t-test); †P ≤ 0.05, ††P ≤ 0.01, †††P ≤ 0.001 indicates the level of significance when the male HAART naïve were compared to the male on HAART; §P ≤ 0.05, §§P ≤ 0.01, §§§P ≤ 0.001 indicates the level of significance when the female HAART naïve were compared to the female on HAART; ‡P ≤ 0.05, ‡‡P ≤ 0.01, ‡‡‡P ≤ 0.001 indicates the level of significance when the male HAART naïve were compared to the female HAART naïve; #P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001 indicates the level of significance when the male on HAART were compared to the female on HAART.